Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 301–400 of 1,001
Prussick, R. B., & Miele, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16239 · Cited by 100
Review of safety and efficacy of approved systemic psoriasis therapies
Kaushik, S. B., & Lebwohl, M. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14246 · Cited by 97
Gupta, S., Ferrada, M. A., & Hasni, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01327 · Cited by 90
“IL-17 has been shown to play an important role in pathogenesis of pSS and can be targeted with monoclonal antibodies like secukinumab (97, 98) and iIxekizumab (99) that are already approved for psoriasis and psoriatic arthritis.”
BackgroundBrunner, H. I., Foeldvari, I., Alexeeva, E. I., Ayaz, N. A., Penadés, I. C., Kasapçopur, Ö., Chasnyk, V. G., Hufnagel, M., Żuber, Z. M., Schulert, G. S., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222849 · Cited by 87
Endothelial Dysfunction as the Common Pathway Linking Obesity, Hypertension and Atherosclerosis
Młynarska, E., Bojdo, K., Frankenstein, H., Krawiranda, K., Kustosik, N., Lisińska, W., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010096 · Cited by 87
“Furthermore, the high cost of these therapies may restrict their availability and use in clinical practice [145].”
Psoriatic arthritis for dermatologists
Gottlieb, A. B., & Merola, J. F. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1605142 · Cited by 102
Karle, A., Spindeldreher, S., & Kolbinger, F. (2016) · mAbs · doi:10.1080/19420862.2015.1136761 · Cited by 86
Asahina, A., Etoh, T., Igarashi, A., Imafuku, S., Saeki, H., Shibasaki, Y., Tomochika, Y., Toyoizumi, S., Nagaoka, M., Ohtsuki, M., et al. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13258 · Cited by 85
Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
Gerdes, S., Pinter, A., Papavassilis, C., & Reinhardt, M. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16004 · Cited by 97
Update on the etiopathogenesis of psoriasis (Review)
Branisteanu, D. E., Cojocaru, C., Diaconu, R., Porumb‐Andrese, E., Alexa, A. I., Nicolescu, A. C., Brihan, I., Bogdănici, C. M., Brănișteanu, G., Dimitriu, A., et al. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11124 · Cited by 108
Cellular Mechanisms of Psoriasis Pathogenesis: A Systemic Review
Wu, M., Dai, C., & Zeng, F. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s420850 · Cited by 103
“Treatment with anti-IL-17A monoclonal antibodies resulted in significant attenuation in patients with psoriasis.(76,77) In addition, inhibition of Th17 cell differentiation by using anti-IL-23 antibodies has shown promising clinical efficacy.”
Backgroundvan Tok, M. N., Na, S., Lao, C. R., Alvi, M., Pots, D., van de Sande, M. G. H., Taurog, J. D., Sedgwick, J. D., Baeten, D., & van Duivenvoorde, L. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01550 · Cited by 95
“In line with these experimental data, emerging clinical trial results in human psoriasis (PsO) indicate that not only IL-17A blockade (8, 9) but also blockade of the p40 (10) or the p19 (11–13) subunit of IL-23 is highly effective.”
Schüler, R., Brand, A., Klebow, S., Wild, J., Veras, F. P., Ullmann, E., Roohani, S., Kolbinger, F., Kossmann, S., Wohn, C., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.09.021 · Cited by 87
Psoriasis and the TNF/IL23/IL17 axis
Furue, K., Ito, T., Tsuji, G., Kadono, T., & Furue, M. (2019) · Giornale Italiano di Dermatologia e Venereologia · doi:10.23736/s0392-0488.18.06202-8 · Cited by 82
Kammuller, M. E., Tsai, T., Griffiths, C. E. M., Kapoor, N., Kolattukudy, P. E., Brees, D., Chibout, S., Safi, J., & Fox, T. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.34 · Cited by 94
Whitlock, S. M., Enos, C., Armstrong, A. W., Gottlieb, A. B., Langley, R. G. B., Lebwohl, M., Merola, J. F., Ryan, C., Siegel, M. P., Weinberg, J. M., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.06.043 · Cited by 91
Self-citationChiu, H., Hui, R. C., Huang, Y., Huang, R.-Y., Chen, K.-L., Tsai, Y., Lai, P.-J., Wang, T., & Tsai, T. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-2989 · Cited by 83
Armstrong, A. W., Soliman, A. M., Betts, K. A., Wang, Y., Gao, Y., Puig, L., & Augustin, M. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00511-1 · Cited by 95
MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation
Monin, L., Gudjonsson, J. E., Childs, E. E., Amatya, N., Xing, X., Verma, A. H., Coleman, B. M., Garg, A. V., Killeen, M., Mathers, A., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601551 · Cited by 82
Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment
Boehncke, W., & Brembilla, N. C. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8634-3 · Cited by 93
“antibodies secukinumab and ixekizumab [10], as well as brodalumab, which neutralizes IL-17A effects through blocking the IL-17A receptor subunit IL17RA [11].”
BackgroundImmune-Epithelial Cross Talk in Regeneration and Repair
Guenin‐Macé, L., Konieczny, P., & Naik, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-062818 · Cited by 87
“IL-17 blockade has been lauded for its success in psoriasis, likely due to restraint of the epithelial hyperproliferative and differentiation pathology (162, 163).”
BackgroundKonen, F. F., Möhn, N., Witte, T., Schefzyk, M., Wiestler, M., Lovric, S., Hufendiek, K., Schwenkenbecher, P., Sühs, K., Friese, M. A., et al. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103312 · Cited by 94
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
Amin, M., No, D. J., Egeberg, A., & Wu, J. J. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0328-3 · Cited by 90
Furue, K., Ito, T., & Furue, M. (2018) · Cytokine · doi:10.1016/j.cyto.2018.08.025 · Cited by 85
Gisondi, P., Talamonti, M., Chiricozzi, A., Piaserico, S., Amerio, P., Balato, A., Bardazzi, F., Calzavara‐Pinton, P., Campanati, A., Cattaneo, A., et al. (2021) · Dermatology and Therapy · doi:10.1007/s13555-020-00475-8 · Cited by 89
A novel molecular disease classifier for psoriasis and eczema
Garzorz‐Stark, N., Krause, L., Lauffer, F., Atenhan, A., Thomas, J., Stark, S. P., Franz, R., Weidinger, S., Balato, A., Mueller, N. S., et al. (2016) · Experimental Dermatology · doi:10.1111/exd.13077 · Cited by 79
2018 APLAR axial spondyloarthritis treatment recommendations
Tam, L., Wei, J. C., Aggarwal, A., Baek, H. J., Cheung, P., Chiowchanwisawakit, P., Dans, L. F., Gu, J., Hagino, N., Kishimoto, M., et al. (2019) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13510 · Cited by 85
Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
Galluzzo, M., Tofani, L., Lombardo, P., Petruzzellis, A., Silvaggio, D., Egan, C. G., Bianchi, L., & Talamonti, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072170 · Cited by 80
An evolution in switching therapy for psoriasis patients who fail to meet treatment goals
Kerdel, F. A., & Zaiac, M. (2015) · Dermatologic Therapy · doi:10.1111/dth.12267 · Cited by 79
“In these studies, PASI 75 response rates at week 12 ranged from 67.0% to 81.6%, supporting the efficacy of IL-17 inhibition in patients with moderate-to-severe psoriasis, including those who failed on previous biologics (15).”
BackgroundInfluentialHuman mast cells capture, store, and release bioactive, exogenous IL-17A
Noordenbos, T., Blijdorp, I. C. J., Chen, S., Stap, J., Mul, E. P. J., Cañete, J. D. D., Lubberts, E., Yeremenko, N. G., & Baeten, D. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3hi1215-542r · Cited by 87
Yiu, Z. Z. N., Exton, L. S., Jabbar‐Lopez, Z. K., Mustapa, M. F. M., Samarasekera, E. J., Burden, A. D., Murphy, R., Owen, C., Parslew, R., Venning, V. V., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.03.035 · Cited by 89
“…et al., 2015; Papp et al., 2005; Strober et al., 2011; Tyring et al., 2006; van de Kerkhof et al., 2008) and secukinumab (Blauvelt et al., 2015; Langley et al., 2014; Paul et al., 2015; Rich et al., 2013) to very low for studies involving infliximab (Yang et al., 2012), adalimumab (Asahina et…”
BackgroundMethodInfluentialReich, K., Rich, P. A., Maari, C., Bissonnette, R., Leonardi, C., Menter, A., Igarashi, A., Klekotka, P. A., Patel, D. R., Li, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17628 · Cited by 86
Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer
Sharma, J., & Larkin, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00324 · Cited by 77
“Anti-IL17A MAb therapy has been approved for treatment of moderate to severe psoriasis plaques, though some patients with moderate to severe psoriasis plaques have been known to suffer from unexpected side effects like nasopharyngitis, arthralgia, and upper respiratory tract infections (Papp et al., 2013; Rich et al.,…”
BackgroundCandida albicans and candidalysin in inflammatory disorders and cancer
Ho, J., Camilli, G., Griffiths, J. S., Richardson, J. P., Kichik, N., & Naglik, J. R. (2021) · Immunology · doi:10.1111/imm.13255 · Cited by 77
Glaubitz, J., Asgarbeik, S., Lange, R., Mazloum, H., Elsheikh, H., Weiß, F. U., & Sendler, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1279539 · Cited by 97
“Both cytokines can be depleted by antibodies, which are already approved for the treatment of psoriasis: Fezakinumab, a monoclonal IL-22 antibody (132) and Secukinumab an antibody raised against IL-17A (133).”
BackgroundInfluentialGenomic alterations driving psoriasis pathogenesis
Singh, S., Pradhan, D., Puri, P., Ramesh, V., Aggarwal, S., Nayek, A., & Jain, A. K. (2018) · Gene · doi:10.1016/j.gene.2018.09.042 · Cited by 91
Thaçi, D., Humeniuk, J. M., Frambach, Y., Bissonnette, R., Goodman, J. J., Shevade, S., Gong, Y., Papavassilis, C., & the STATURE study group (2015) · British Journal of Dermatology · doi:10.1111/bjd.13814 · Cited by 79
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations
Gossec, L., Coates, L. C., de Wit, M. P. T., Kavanaugh, A., Ramiro, S., Mease, P. J., Ritchlin, C. T., van der Heijde, D. M. F. M., & Smolen, J. S. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.183 · Cited by 86
Japanese guidance for use of biologics for psoriasis (the 2019 version)
Saeki, H., Terui, T., Morita, A., Sano, S., Imafuku, S., Asahina, A., Komine, M., Etoh, T., Igarashi, A., Torii, H., et al. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15196 · Cited by 77
Elewski, B. E., Baddley, J. W., Deodhar, A. A., Magrey, M., Rich, P. A., Soriano, E. R., Soung, J., Bao, W., Keininger, D. L., Marfo, K., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.3257 · Cited by 77
T‐cell subsets in the skin and their role in inflammatory skin disorders
Krohn, I. K., Aerts, J. L., Breckpot, K., Goyvaerts, C., Knol, E. F., van Wijk, F., & Gutermuth, J. (2021) · Allergy · doi:10.1111/all.15104 · Cited by 93
Marzo‐Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Delicha, E. M., Rohrer, S., & Richards, H. B. (2017) · RMD Open · doi:10.1136/rmdopen-2017-000592 · Cited by 78
Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion
Wang, J., Bhatia, A., Cleveland, N. K., Gupta, N., Dalal, S. R., Rubin, D. T., & Sakuraba, A. (2018) · ACG Case Reports Journal · doi:10.14309/crj.2018.56 · Cited by 77
Bagel, J., Nia, J. K., Hashim, P. W., Patekar, M., de Vera, A., Hugot, S., Sheng, K., Xia, S., Gilloteau, I., Muscianisi, E., et al. (2018) · Dermatology and Therapy · doi:10.1007/s13555-018-0265-y · Cited by 75
Does YouTube provide high quality information? Assessment of secukinumab videos
Koçyiğit, B. F., & Akaltun, M. S. (2019) · Rheumatology International · doi:10.1007/s00296-019-04322-8 · Cited by 82
Reich, K., Sullivan, J. R., Arenberger, P., Jazayeri, S., Mrowietz, U., Augustin, M., Elewski, B. E., You, R., Regnault, P., & Frueh, J. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19262 · Cited by 75
The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases
Țiburcă, L., Bembea, M., Zaha, D. C., Jurcă, A. D., Vesa, C. M., Rațiu, I. A., & Jurca, C. M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44050127 · Cited by 85
Visvanathan, S., Baum, P., Vinisko, R., Schmid, R., Flack, M., Lalovic, B. B., Kleiner, O., Fuentes‐Duculan, J., Garcet, S., Davis, J. W., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.042 · Cited by 73
Swindell, W. R., Sarkar, M. K., Liang, Y., Xing, X., & Gudjonsson, J. E. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.04.035 · Cited by 73
“…(focused on a subset of psoriasis DEGs) (Swindell et al., 2015a), and also resonate with clinical data demonstrating efficacy of anti-IL-17A therapy for moderate-to-severe psoriasis (e.g., secukinumab, ixekizumab, brodalumab) (Griffiths et al., 2015; Langley et al., 2014; Lebwohl et al., 2015).”
BackgroundFrieder, J., Kivelevitch, D. N., Haugh, I. M., Watson, I., & Menter, A. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.893 · Cited by 80
“3% for etanercept and 0% for secukinumab).(62) Secukinumab and ustekinumab also showed similar safety profiles in the CLEAR trial with no unexpected AEs observed.”
BackgroundResultInfluentialDrug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
Egeberg, A., Bryld, L. E., & Skov, L. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.03.048 · Cited by 73
Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
Ji, E., & Lee, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115770 · Cited by 86
The Role of IL-17 Cytokines in Psoriasis
Mosca, M., Hong, J. J., Hadeler, E. K., Hakimi, M., Liao, W. J., & Bhutani, T. (2021) · Dove Medical Press (Taylor and Francis Group) · Cited by 73
Gordon, K. B., Blauvelt, A., Foley, P. A., Song, M., Wasfi, Y. S., Randazzo, B. P., Shen, Y., You, Y., & Griffiths, C. E. M. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16008 · Cited by 76
Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis
Pepple, K. L., & Lin, P. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.05.014 · Cited by 75
Notario, J., Deza, G., Vilarrasa, E., Valentí, F., Muñoz, C., Mollet, J., Rocamora, V., Carrascosa, J. M., del Alcázar, E., Alsina, M., et al. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1528000 · Cited by 79
“3% of the patients included in the ERASURE and FIXTURE study, respectively (4).”
BackgroundMethodResultInfluentialHistone modifications associated with biological drug response in moderate‐to‐severe psoriasis
Ovejero-Benito, M. C., Reolid, A., Sánchez‐Jiménez, P., Saiz‐Rodríguez, M., Muñoz‐Aceituno, E., Llamas‐Velasco, M., Martín‐Vílchez, S., Cabaleiro, T., Román, M. C., Ochoa, D., et al. (2018) · Experimental Dermatology · doi:10.1111/exd.13790 · Cited by 80
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists
Fauber, B. P., Gobbi, A., Robarge, K. D., Zhou, A., Barnard, A., Cao, J., Deng, Y., Eidenschenk, C., Everett, C., Ganguli, A., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.055 · Cited by 75
Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)
Benezeder, T., & Wolf, P. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00766-z · Cited by 85
Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model
Aksentijevich, M., Lateef, S. S., Anzenberg, P., Dey, A. K., & Mehta, N. N. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.001 · Cited by 81
“Additionally, anti-IL17 therapy carries great interest in psoriasis given the immense success it has on reducing psoriasis disease severity (74).”
BackgroundReal‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies
Augustin, M., Jullien, D., Martin, A., & Peralta, C. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16180 · Cited by 72
IL-17 in wound repair: bridging acute and chronic responses
Mu, X., Gu, R., Tang, M., Wu, X., He, W., & Nie, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01668-w · Cited by 85
“Their ability to selectively inhibit IL-17 A has proven beneficial in reducing inflammation and improving clinical outcomes in diseases such as psoriasis and ankylosing spondylitis [52, 53].”
BackgroundPopulation Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Bruin, G. J. M., Loesche, C., Nyirady, J., & Sander, O. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.876 · Cited by 78
Kim, J. Y., Ahn, J., Kim, J., Choi, M., Jeon, H., Choe, K., Lee, D. Y., Kim, P., & Jon, S. (2018) · ACS Nano · doi:10.1021/acsnano.8b02330 · Cited by 72
Mease, P. J., Kavanaugh, A., Reimold, A. M., Tahir, H., Rech, J., Hall, S., Geusens, P., Pellet, P., Delicha, E. M., Mpofu, S., et al. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000723 · Cited by 76
“Candida infections observed during this study are consistent with results from phase III studies, including the FUTURE 1 core study, in patients with PsA(17) 28 and psoriasis.(15) All cases were mild to moderate in severity, did not lead to discontinuation and were managed with standard antifungal therapy.”
ResultLee, B., Kwon, J.-T., Jeong, Y., Caris, H., Oh, D., Feng, M., Davila Mejia, I., Zhang, X., Ishikawa, T., Watson, B. R., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.005 · Cited by 70
Mechanistic rationales for targeting interleukin-17A in spondyloarthritis
Raychaudhuri, S. P., & Raychaudhuri, S. K. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1249-5 · Cited by 75
“In psoriasis clinical trials, secukinumab’s side-effect profile was similar to that of the TNF-α inhibitor etanercept and the IL-12/IL-23 antagonist ustekinumab, with no safety signals indicating an increased risk for serious adverse events of interest, including malignancy, infection, or induction of autoimmune disea…”
BackgroundPathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children
Chovatiya, R., & Silverberg, J. I. (2019) · Children · doi:10.3390/children6100108 · Cited by 87
Yin and yang of interleukin-17 in host immunity to infection
Das, S., & Khader, S. A. (2017) · F1000Research · doi:10.12688/f1000research.10862.1 · Cited by 78
“IL-17 plays an immunologically important host protective role against fungal pathogens such as Candida albicans 118 , Cryptococcus neoformans 119 , Pneumocystis carinii 120 , and Aspergillus fumigatus 121 in both humans and mice.”
BackgroundInfluentialEgeberg, A., Andersen, Y. M. F., Halling, A., Alignahi, F., Thyssen, J. P., Burge, R. T., & Mallbris, L. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15920 · Cited by 73
Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders
Balato, A., Scala, E., Balato, N., Caiazzo, G., Caprio, R. D., Monfrecola, G., Raimondo, A., Lembo, S., & Ayala, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1363884 · Cited by 74
Reich, K., Papp, K. A., Armstrong, A. W., Wasfi, Y. S., Li, S., Shen, Y., Randazzo, B. P., Song, M., & Kimball, A. B. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17454 · Cited by 73
Uemura, M., Trinh, V. A., Haymaker, C., Jackson, N., Kim, D. W., Allison, J. P., Sharma, P., Vence, L., Bernatchez, C., Hwu, P., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0309-7 · Cited by 69
“In fact, secukinumab and ixekizumab, both IL-17A antibodies, have been FDA-approved for the treatment of plaque psoriasis based on phase 3 trials [14, 15].”
Bissonnette, R., Luger, T. A., Thaçi, D., Toth, D., Messina, I., You, R., Guana, A., Fox, T., Papavassilis, C., Gilloteau, I., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15706 · Cited by 76
IL-17 Receptor A Maintains and Protects the Skin Barrier To Prevent Allergic Skin Inflammation
Floudas, A., Saunders, S. P., Moran, T., Schwartz, C., Hams, E., Fitzgerald, D. C., Johnston, J. A., Ogg, G. S., McKenzie, A. N., Walsh, P. T., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602185 · Cited by 69
Psoriasis: Recent progress in molecular‐targeted therapies
Honma, M., & Hayashi, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15727 · Cited by 77
Gordon, K. B., Langley, R. G. B., Warren, R. B., Okubo, Y., Gold, L. S., Merola, J. F., Peterson, L., Wixted, K., Cross, N., Deherder, D., et al. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.1185 · Cited by 74
Self-citationLipid metabolism in Th17 cell function
Kanno, T., Nakajima, T., Miyako, K., & Endo, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108411 · Cited by 74
Ali, F. M., Cueva, A., Vyas, J., Atwan, A. A., Salek, S., Finlay, A. Y., & Piguet, V. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14788 · Cited by 79
Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients
Regnault, M. M., Konstantinou, M. P., Khemis, A., Poulin, Y. P., Bourcier, M., Amelot, F., Livideanu, C. B., & Paul, C. F. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14387 · Cited by 70
Körber, A., Papavassilis, C., Bhosekar, V., & Reinhardt, M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0520-z · Cited by 74
“The study design, methods, and results of all three studies were previously described [10, 13, 14].”
MethodReich, K., Puig, L., Szepietowski, J. C., Paul, C. F., Lacour, J. ‐., Tsianakas, A., Sieder, C., Rissler, M., Pournara, E., & Orsenigo, R. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18143 · Cited by 67
Shear, N. H., Betts, K. A., Soliman, A. M., Joshi, A. D., Wang, Y., Zhao, J., Gisondi, P., Sinvhal, R., & Armstrong, A. W. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.02.057 · Cited by 74
TH17 Cell and Epithelial Cell Crosstalk during Inflammatory Bowel Disease and Carcinogenesis
Kempski, J., Brockmann, L., Gagliani, N., & Huber, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01373 · Cited by 67
Bacterial Translocation as Inflammatory Driver in Crohn’s Disease
Linares, R., Francés, R., Gutiérrez, A., & Juanola, O. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703310 · Cited by 74
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists
Liu, S., Dakin, L. A., Li, X., Withka, J. M., Sahasrabudhe, P. V., Li, W., Banker, M. E., Balbo, P., Shanker, S., Chrunyk, B. A., et al. (2016) · Scientific Reports · doi:10.1038/srep30859 · Cited by 69
Chronic Pruritus: Current and Emerging Treatment Options
Pereira, M. P., & Ständer, S. (2017) · Drugs · doi:10.1007/s40265-017-0746-9 · Cited by 72
“antagonist, showed efficacy against plaque psoriasis and the concomitant pruritus [59] and was superior to ustek-”
BackgroundInnate Immunity to Mucosal Candida Infections
Verma, A., Gaffen, S., & Swidergall, M. (2017) · Journal of Fungi · doi:10.3390/jof3040060 · Cited by 66
“Moreover, neutralizing antibodies against IL-17 predispose individuals to chronic mucocutaneous candidiasis (CMC), commonly seen in AIRE-deficient patients [99,100] and occasionally in individuals undergoing anti-IL-17 biologic therapy for autoimmunity [101].”
BackgroundRegulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation
Hartwig, T., Zwicky, P., Schreiner, B., Yawalkar, N., Cheng, P. F., Navarini, A. A., Dummer, R., Flatz, L., Conrad, C., Schlapbach, C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.012 · Cited by 72
Yamada, A., Wang, J., Komaki, Y., Komaki, F., Micić, D., & Sakuraba, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15397 · Cited by 69
Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis
Tomalin, L. E., Russell, C. B., Garcet, S., Ewald, D. A., Klekotka, P. A., Nirula, A., Norsgaard, H., Suárez‐Fariñas, M., & Krueger, J. G. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.10.041 · Cited by 69
Canavan, T. N., Elmets, C. A., Cantrell, W., Evans, J. M., & Elewski, B. E. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0162-4 · Cited by 72
“0 % of patients treated with etanercept in the FIXTURE trial [17].”
BackgroundMethodInfluentialDrug survival rates and reasons for drug discontinuation in psoriasis
Arnold, T., Schaarschmidt, M., Herr, R. M., Fischer, J. E., Goerdt, S., & Peitsch, W. K. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13152 · Cited by 70
Galluzzo, M., Talamonti, M., SIMONE, C. D., D’Adamio, S., Moretta, G., Tambone, S., Caldarola, G., Fargnoli, M. C., Peris, K., & Bianchi, L. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1481503 · Cited by 65
“At week 12, 81.6% of patients treated with secukinumab 300 mg in the ERASURE study and 77.1% in the FIXTURE study had a 75% reduction in Psoriasis Area and Severity Index (PASI) scores (PASI75) compared with 44.0% of patients receiving etanercept [11].”
ResultInfluentialMartora, F., Megna, M., Battista, T., Potestio, L., Annunziata, M. C., Marasca, C., Villani, A., & Fabbrocini, G. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s391356 · Cited by 72
“FDA approved the drug for the following indications: moderate to severe psoriasis, hypertrophic palmoplantar psoriasis, generalized pustular psoriasis, psoriatic arthritis and ankylosing spondylitis.(65) It has been used off-label for rheumatoid arthritis and hidradenitis suppurativa.”
Olsson, R. I., Xue, Y., von Berg, S., Aagaard, A., McPheat, J., Hansson, E. L., Bernström, J., Hansson, P., Jirholt, J., Grindebacke, H., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500432 · Cited by 70
Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation
Golden, J. B., Groft, S. G., Squeri, M. V., Debanne, S. M., Ward, N. L., McCormick, T. S., & Cooper, K. D. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402307 · Cited by 73
Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis
Whibley, N., Tritto, E., Traggiai, E., Kolbinger, F., Moulin, P., Brees, D., Coleman, B. M., Mamo, A. J., Garg, A. V., Jaycox, J. R., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.4a0915-428r · Cited by 65
Martin, J. P. D., Wolk, K., Bériou, G., Abidi, A., Witte‐Händel, E., Louvet, C., Kokolakis, G., Drujont, L., Dumoutier, L., Renauld, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700021 · Cited by 73
The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond
Dubash, S., Bridgewood, C., McGonagle, D., & Marzo‐Ortega, H. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1561281 · Cited by 72
“There was no significant increase in the risk of bacterial or fungal infections in the clinical trials and the overall infection risk appears to be similar to TNF inhibition which has also been demonstrated against etanercept in head-to-head phase 3 trials for PsO [50,54].”
BackgroundInfluential
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.